Home / Reports

Reports

EMA report shows generics applications down but biosimilars up

EMA’s mid-year report for 2012 has shown that the number of generics applications is much lower than the agency has predicted, while for biosimilars it is the opposite.

Stakeholders are key allies for biosimilar producers

Many different drug developers could potentially contribute to the biosimilars market, which is projected to expand rapidly, achieving sales of between US$1.9–2.6 billion by 2015. It is vital, however, to take into account the requirements of different stakeholders in order to develop appropriate strategies for success, as highlighted in a recent IMS Health report [1].

Australian patients ‘very positive’ about generics

A new survey shows 75% of Australians believe that the government should offer a price discount to consumers who choose generics.

ABPI concerned about medicines misconceptions

The Association of the British Pharmaceutical Industry (ABPI) represents innovative research-based biopharmaceutical companies in the UK. In a new survey commissioned by the association issues of misunderstandings by the British public have been highlighted regarding the cost and value of medicines in the UK.

2020 outlook for biosimilars: opportunities and hurdles

Many different factors will influence the future growth of the biosimilars market in different world regions, both in terms of access to biosimilars and uptake. Producers will need to re-evaluate their own capacity to enter the biosimilars market and develop both in-house strategies and external alliances in order to gain most from potential value of biosimilars.

Growing economies, growing markets: a bright future for biosimilars

The biosimilars market, currently small and focused on a few disease areas and countries, is likely to grow considerably over the coming years, particularly in the US and emerging economies such as Brazil and South Korea. An analysis by IMS Health indicates that while this situation is potentially highly lucrative, careful planning and negotiation by producers will be required to make the most of the burgeoning markets [1].

Positioning of biosimilars: commodity versus differentiated

How to market a new biosimilar is a key question, especially when taking into consideration the costs that are associated with developing a biosimilar. Whether the biosimilar will be a bulk (commodity) product or a differentiated product can have significant impact on the uptake of the biosimilar.

Generics reduce England’s drug spending

According to a new report from the National Health Service in England, published on 31 July 2012, despite a 3.8% increase in the number of prescriptions dispensed in 2011 compared to 2010, spending on pharmaceuticals has decreased by 0.3%.

European uptake of biosimilars

Despite the fact that Europe accounts for 80% of global spending on biosimilars, uptake varies significantly between different countries. This variation is mostly attributed to differences in the healthcare systems between different countries, but is also due to differing attitudes in the different countries, see Figure 1. However, continuing pressure on healthcare budgets is expected to force a change in attitudes and cause an increase in the use of lower cost biosimilars across Europe.

Biosimilars: key players and global market trends

Biosimilars are approaching a turning point in their evolution, although positive moves are being made, there is still much that has to change in order to create a global market that can sustain biosimilars [1].